These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 34139124)

  • 21. Expression/localization patterns of sirtuins (SIRT1, SIRT2, and SIRT7) during progression of cervical cancer and effects of sirtuin inhibitors on growth of cervical cancer cells.
    Singh S; Kumar PU; Thakur S; Kiran S; Sen B; Sharma S; Rao VV; Poongothai AR; Ramakrishna G
    Tumour Biol; 2015 Aug; 36(8):6159-71. PubMed ID: 25794641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective SIRT2 inhibitors as promising anticancer therapeutics: An update from 2016 to 2020.
    Roshdy E; Mustafa M; Shaltout AE; Radwan MO; Ibrahim MAA; Soliman ME; Fujita M; Otsuka M; Ali TFS
    Eur J Med Chem; 2021 Nov; 224():113709. PubMed ID: 34303869
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis of certain benzothieno[3,2-d]pyrimidine derivatives as a selective SIRT2 inhibitors.
    Khalil NA; Ahmed EM; Zaher AF; El-Zoghbi MS; Sobh EA
    Eur J Med Chem; 2020 Feb; 187():111926. PubMed ID: 31812033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Finding Potent Sirt Inhibitor in Coffee: Isolation, Confirmation and Synthesis of Javamide-II (N-Caffeoyltryptophan) as Sirt1/2 Inhibitor.
    Park JB
    PLoS One; 2016; 11(3):e0150392. PubMed ID: 26986569
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure activity study of S-trityl-cysteamine dimethylaminopyridine derivatives as SIRT2 inhibitors: Improvement of SIRT2 binding and inhibition.
    Radwan MO; Ciftci HI; Ali TFS; Koga R; Tateishi H; Nakata A; Ito A; Yoshida M; Fujita M; Otsuka M
    Bioorg Med Chem Lett; 2020 Oct; 30(19):127458. PubMed ID: 32755678
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of a Selective SIRT2 Inhibitor and Its Anti-breast Cancer Activity.
    Shah AA; Ito A; Nakata A; Yoshida M
    Biol Pharm Bull; 2016; 39(10):1739-1742. PubMed ID: 27725455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of a potent small molecule SIRT1/2 inhibitor with anticancer effects.
    Choi G; Lee J; Ji JY; Woo J; Kang NS; Cho SY; Kim HR; Ha JD; Han SY
    Int J Oncol; 2013 Oct; 43(4):1205-11. PubMed ID: 23900402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacophore modeling and virtual screening studies to identify novel selective SIRT2 inhibitors.
    Eren G; Bruno A; Guntekin-Ergun S; Cetin-Atalay R; Ozgencil F; Ozkan Y; Gozelle M; Kaya SG; Costantino G
    J Mol Graph Model; 2019 Jun; 89():60-73. PubMed ID: 30870650
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure-based design of pseudopeptidic inhibitors for SIRT1 and SIRT2.
    Huhtiniemi T; Salo HS; Suuronen T; Poso A; Salminen A; Leppänen J; Jarho E; Lahtela-Kakkonen M
    J Med Chem; 2011 Oct; 54(19):6456-68. PubMed ID: 21895016
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current advances in the synthesis and antitumoral activity of SIRT1-2 inhibitors by modulation of p53 and pro-apoptotic proteins.
    Botta G; De Santis LP; Saladino R
    Curr Med Chem; 2012; 19(34):5871-84. PubMed ID: 22998567
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of bicyclic pyrazoles as class III histone deacetylase SIRT1 and SIRT2 inhibitors.
    Therrien E; Larouche G; Nguyen N; Rahil J; Lemieux AM; Li Z; Fournel M; Yan TP; Landry AJ; Lefebvre S; Wang JJ; MacBeth K; Heise C; Nguyen A; Besterman JM; Déziel R; Wahhab A
    Bioorg Med Chem Lett; 2015 Jun; 25(12):2514-8. PubMed ID: 25971769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enzymatic and Biological Characterization of Novel Sirtuin Modulators against Cancer.
    Carafa V; Poziello A; Della Torre L; Giovannelli P; Di Donato M; Safadeh E; Yu Z; Baldi A; Castoria G; Tomaselli D; Mai A; Rotili D; Nebbioso A; Altucci L
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31726691
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of 2-((4,6-dimethylpyrimidin-2-yl)thio)-N-phenylacetamide derivatives as new potent and selective human sirtuin 2 inhibitors.
    Yang L; Ma X; Yuan C; He Y; Li L; Fang S; Xia W; He T; Qian S; Xu Z; Li G; Wang Z
    Eur J Med Chem; 2017 Jul; 134():230-241. PubMed ID: 28415012
    [TBL] [Abstract][Full Text] [Related]  

  • 34. N(epsilon)-Modified lysine containing inhibitors for SIRT1 and SIRT2.
    Huhtiniemi T; Suuronen T; Lahtela-Kakkonen M; Bruijn T; Jääskeläinen S; Poso A; Salminen A; Leppänen J; Jarho E
    Bioorg Med Chem; 2010 Aug; 18(15):5616-25. PubMed ID: 20630764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyclic peptide-based potent and selective SIRT1/2 dual inhibitors harboring N
    Chen D; Zheng W
    Bioorg Med Chem Lett; 2016 Nov; 26(21):5234-5239. PubMed ID: 27707605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The discovery of a highly selective 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one SIRT2 inhibitor that is neuroprotective in an in vitro Parkinson's disease model.
    Di Fruscia P; Zacharioudakis E; Liu C; Moniot S; Laohasinnarong S; Khongkow M; Harrison IF; Koltsida K; Reynolds CR; Schmidtkunz K; Jung M; Chapman KL; Steegborn C; Dexter DT; Sternberg MJ; Lam EW; Fuchter MJ
    ChemMedChem; 2015 Jan; 10(1):69-82. PubMed ID: 25395356
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Simplification of the tetracyclic SIRT1-selective inhibitor MC2141: coumarin- and pyrimidine-based SIRT1/2 inhibitors with different selectivity profile.
    Rotili D; Carafa V; Tarantino D; Botta G; Nebbioso A; Altucci L; Mai A
    Bioorg Med Chem; 2011 Jun; 19(12):3659-68. PubMed ID: 21306905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hit evaluation results in 5-benzyl-1,3,4-thiadiazole-2-carboxamide based SIRT2-selective inhibitor with improved affinity and selectivity.
    Gozelle M; Kaya SG; Aksel AB; Ozkan E; Bakar-Ates F; Ozkan Y; Eren G
    Bioorg Chem; 2022 Jun; 123():105746. PubMed ID: 35358824
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Virtual screening approach of sirtuin inhibitors results in two new scaffolds.
    Kokkonen P; Kokkola T; Suuronen T; Poso A; Jarho E; Lahtela-Kakkonen M
    Eur J Pharm Sci; 2015 Aug; 76():27-32. PubMed ID: 25936698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 3-(N-arylsulfamoyl)benzamides, inhibitors of human sirtuin type 2 (SIRT2).
    Choi SH; Quinti L; Kazantsev AG; Silverman RB
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2789-93. PubMed ID: 22446090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.